Literature DB >> 23302578

Chromosomal and plasmid-mediated fluoroquinolone resistance mechanisms among broad-spectrum-cephalosporin-resistant Escherichia coli isolates recovered from companion animals in the USA.

Bashar W Shaheen1, Rajesh Nayak, Steven L Foley, Dawn M Boothe.   

Abstract

OBJECTIVES: To determine the prevalence of plasmid-mediated quinolone resistance (PMQR) determinants and investigate mutations in gyrase and topoisomerase genes that may contribute to increased fluoroquinolone resistance in canine and feline Escherichia coli isolates in the USA that displayed reduced susceptibility to extended-spectrum cephalosporins. This study was undertaken because previous epidemiological studies identified a potential correlation between extended-spectrum cephalosporins and fluoroquinolone resistance.
METHODS: Isolates (n = 54) with reduced susceptibility to ceftazidime or cefotaxime were screened by PCR for the presence of PMQR determinants and gyrase and topoisomerase genes were sequenced. Isolates were further characterized by conjugation and phylogenetic analyses.
RESULTS: PMQR determinants aac(6')-Ib-cr, qnrS and qepA were identified in 30, 23 and 5 isolates, respectively. Multiple mutations were identified in the quinolone resistance-determining region, including the novel substitutions of Glu-84 → Ala and Leu-88 → Gln in ParC and Arg-432 → Ser and Glu-460 → Val in ParE. The isolate that exhibited the highest level of enrofloxacin resistance (MIC > 256 mg/L) had a double mutation in gyrA (Ser-83 → Leu and Asp-87 → Asn) and a triple mutation in parC (Ser-80 → Ile, Glu-84 → Gly and a novel mutation, Leu-88 → Gln). The presence of PMQR genes increased the ciprofloxacin MIC values 4-fold to 8-fold in transconjugants relative to the recipient strain. Approximately 39% of the isolates belonged to phylogenetic group D and 30% to group B2, which typically contain an increased number of virulence determinants compared with other groups.
CONCLUSIONS: Novel mutations in topoisomerase genes and PMQR determinants aac(6')-Ib-cr, qnrS and qepA genes were detected among extended-spectrum β-lactamase-producing E. coli in the USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23302578      PMCID: PMC4415085          DOI: 10.1093/jac/dks514

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  18 in total

1.  Rapid and simple determination of the Escherichia coli phylogenetic group.

Authors:  O Clermont; S Bonacorsi; E Bingen
Journal:  Appl Environ Microbiol       Date:  2000-10       Impact factor: 4.792

2.  qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States.

Authors:  A Robicsek; J Strahilevitz; D F Sahm; G A Jacoby; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

3.  High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.

Authors:  Junying Ma; Zhenling Zeng; Zhangliu Chen; Xiaogang Xu; Xiaoying Wang; Yuting Deng; Dianhong Lü; Liangzong Huang; Yunyuan Zhang; Jianhua Liu; Minggui Wang
Journal:  Antimicrob Agents Chemother       Date:  2008-10-20       Impact factor: 5.191

4.  Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.

Authors:  Constança Pomba; Joana Diniz da Fonseca; Bruno Coelho Baptista; José Duarte Correia; Luis Martínez-Martínez
Journal:  Antimicrob Agents Chemother       Date:  2008-11-10       Impact factor: 5.191

5.  Molecular characterization of resistance to extended-spectrum cephalosporins in clinical Escherichia coli isolates from companion animals in the United States.

Authors:  Bashar W Shaheen; Rajesh Nayak; Steven L Foley; Ohgew Kweon; Joanna Deck; Miseon Park; Fatemeh Rafii; Dawn M Boothe
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

6.  Escherichia coli strains isolated from the uterus and urinary bladder of bitches suffering from pyometra: comparison by restriction enzyme digestion and pulsed-field gel electrophoresis.

Authors:  Ragnvi Hagman; Inger Kühn
Journal:  Vet Microbiol       Date:  2002-01-03       Impact factor: 3.293

7.  Evaluation of the contribution of gyrA mutation and efflux pumps to fluoroquinolone and multidrug resistance in pathogenic Escherichia coli isolates from dogs and cats.

Authors:  Bashar W Shaheen; Dawn M Boothe; Omar A Oyarzabal; Chengming Wang; Calvin M Johnson
Journal:  Am J Vet Res       Date:  2011-01       Impact factor: 1.156

8.  Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.

Authors:  Kunikazu Yamane; Jun-ichi Wachino; Satowa Suzuki; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

Review 9.  Plasmid-mediated quinolone resistance: a multifaceted threat.

Authors:  Jacob Strahilevitz; George A Jacoby; David C Hooper; Ari Robicsek
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

10.  Antimicrobial resistance profiles and clonal relatedness of canine and feline Escherichia coli pathogens expressing multidrug resistance in the United States.

Authors:  B W Shaheen; D M Boothe; O A Oyarzabal; T Smaha
Journal:  J Vet Intern Med       Date:  2010 Mar-Apr       Impact factor: 3.333

View more
  9 in total

Review 1.  Plasmid-mediated quinolone resistance.

Authors:  George A Jacoby; Jacob Strahilevitz; David C Hooper
Journal:  Microbiol Spectr       Date:  2014-10

2.  Emergence of a New Delhi metallo-β-lactamase (NDM-1)-encoding gene in clinical Escherichia coli isolates recovered from companion animals in the United States.

Authors:  Bashar W Shaheen; Rajesh Nayak; Dawn M Boothe
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

3.  Antimicrobial resistance trends among canine Escherichia coli isolates obtained from clinical samples in the northeastern USA, 2004-2011.

Authors:  Kevin J Cummings; Victor A Aprea; Craig Altier
Journal:  Can Vet J       Date:  2015-04       Impact factor: 1.008

4.  Quinolone co-resistance in ESBL- or AmpC-producing Escherichia coli from an Indian urban aquatic environment and their public health implications.

Authors:  Priyanka Bajaj; Pawan Kumar Kanaujia; Nambram Somendro Singh; Shalu Sharma; Shakti Kumar; Jugsharan Singh Virdi
Journal:  Environ Sci Pollut Res Int       Date:  2015-10-26       Impact factor: 4.223

5.  Multidrug resistance in Escherichia coli strains isolated from infections in dogs and cats in Poland (2007-2013).

Authors:  Magdalena Rzewuska; Michał Czopowicz; Magdalena Kizerwetter-Świda; Dorota Chrobak; Borys Błaszczak; Marian Binek
Journal:  ScientificWorldJournal       Date:  2015-01-15

6.  Determination of antibiotic resistance genes in relation to phylogenetic background in Escherichia coli isolates from fecal samples of healthy pet cats in Kerman city.

Authors:  Baharak Akhtardanesh; Reza Ghanbarpour; Sadaf Ganjalikhani; Parisa Gazanfari
Journal:  Vet Res Forum       Date:  2016-12-15       Impact factor: 1.054

7.  Detection of plasmid-mediated quinolone resistance in clinical isolates of Enterobacteriaceae strains in Hamadan, West of Iran.

Authors:  Amir Majlesi; Reza Kamali Kakhki; Amir Sasan Mozaffari Nejad; Rasoul Yousefi Mashouf; Amir Roointan; Malek Abazari; Mohammad Yousef Alikhani
Journal:  Saudi J Biol Sci       Date:  2016-12-19       Impact factor: 4.219

8.  Veterinary Hospital Dissemination of CTX-M-15 Extended-Spectrum Beta-Lactamase-Producing Escherichia coli ST410 in the United Kingdom.

Authors:  Dorina Timofte; Iuliana Elena Maciuca; Nicola J Williams; Andrew Wattret; Vanessa Schmidt
Journal:  Microb Drug Resist       Date:  2016-06-17       Impact factor: 3.431

9.  Escherichia coli-associated granulomatous colitis in dogs treated according to antimicrobial susceptibility profiling.

Authors:  Alison C Manchester; Belgin Dogan; Yongli Guo; Kenneth W Simpson
Journal:  J Vet Intern Med       Date:  2020-12-15       Impact factor: 3.175

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.